Evidence map›Paper›PMID 42794388›Full record

ArticleGels (Basel, Switzerland)2026

Development of Pharmabiotic Gel-Serums with

Pervin Soyer, A Alper Öztürk

Abstract read
In one paragraph

Article in Gels (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Pervin SoyerDepartment of Pharmaceutical Microbiology, Faculty of Pharmacy, Anadolu University, Eskisehir 26470, Turkey.ORCID 0000-0002-6258-1993
A Alper ÖztürkDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, Eskisehir 26470, Turkey.ORCID 0000-0001-9596-0538

Funding

Anadolu University YTT-2024-2606
6 · The paper itself

Abstract

Postbiotic and paraprobiotic preparations are increasingly investigated as non-viable microbial-derived components for topical formulation development, offering an alternative to systems containing live microorganisms. However, their physicochemical and biological performance may depend strongly on the polymeric carrier, and direct comparisons of postbiotic and paraprobiotic fractions derived from the same microbial source in different gel matrices remain limited. This study aimed to develop and comparatively evaluate Carbopol

Indexed as

antibiofilm activityantimicrobial activityantioxidant activityCarbopol®chitosanLacticaseibacillus caseiparaprobioticpharmabiotic gel-serumpostbiotic

Identifiers

PMID42794388
PMCPMC13606687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.